Expression on the functional domain of Ov-ASP-1 protein in Eschervchia coli and its adjuvanticity in vivo
GUO Jing-jing1, NING Xiu-zhe2, YANG-yi2, KOU Zhi-hua2, ZHOU Yu-sen2
1. Department of Laboratory Medicine,The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University,Wenzhou 325027, China;; 2. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
Abstract:We aimed to find and express the functional domain of Ov-ASP-1, which has similar adjuvanticity to Ov-ASP-1. Through the binding results of the monoclonal antibodies (mAb) specific to the Ov-ASP-1 and peptides of Ov-ASP-1, which was prepared previously, we designed a functional domain ASPPRM. Then, ASPPRM protein was expressed in E. coli, purified by affinity chromatography with Ni-charged resin and refolded by gradient dialysis to soluble form. The purified ASPPRM was intramuscularly immunized to BALB/c mice to evaluate its biologicalactivity. The functional domain ASPPRM was expressed in E. coli in the form of inclusion bodies. ASPPRM enhanced the immunogenicity of OVA in BALB/c mice. The ASPPRM protein was obtained, which had similar adjuvanticity to Ov-ASP-1. This research may lay a foundation for the following work on the adjuvanticity of ASPPRM and the functional domain of Ov-ASP-1.
郭晶晶, 宁秀哲, 杨裔, 寇志华, 周育森. 新型疫苗佐剂Ov-ASP-1佐剂活性功能区的设计、表达及生物学特性研究[J]. 中国人兽共患病学报, 2018, 34(9): 788-793.
GUO Jing-jing, NING Xiu-zhe, YANG-yi, KOU Zhi-hua, ZHOU Yu-sen. Expression on the functional domain of Ov-ASP-1 protein in Eschervchia coli and its adjuvanticity in vivo. Chinese Journal of Zoonoses, 2018, 34(9): 788-793.
[1] MacDonald AJ, Cao L, He Y, et al. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens[J]. Vaccine, 2005, 23(26): 3446-3452. DOI:10.1016/j.vaccine.2005.01.098 [2] MacDonald A, Libri N, Lustigman S, et al. A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action[J]. Clinical & Experimental Immunology, 2008, 152(2): 265-273. DOI:10.1083/jcb.200309081 [3] Jiang J, Fisher EM, Hensley SE, et al.Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines[J]. Vaccine, 2014, 32(23): 2696-702.DOI:10.1016/j.vaccine.2014.03.046 [4] Wang J, Tricoche N, Du L, et al.The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates[J]. PloS one, 2012, 7(5): e37019.DOI: 10.1371/journal.pone.0037019 [5] Asojo OA, Goud G, Dhar K, et al.X-ray structure of Na-ASP-2, a pathogenesis-related-1 protein from the nematode parasite, Necator americanus, and a vaccine antigen for human hookworm infection[J]. Journal of molecular biology, 2005, 346(3): 801-814. DOI:10.1016/j.jmb.2004.12.023 [6] Gibbs GM, Roelants K, O’Bryan MK. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, cancer, and immune defense[J]. Endocrine reviews, 2008, 29(7): 865-897. DOI:10.1210/er.2008-0032 [7] Asojo OA.Structure of a two-CAP-domain protein from the human hookworm parasite Necator americanus[J]. Acta crystallographica Section D, Biological crystallography, 2011, 67(Pt 5): 455-862. DOI:10.1107/S0907444911008560 [8] 郭晶晶, 于虹, 杨裔, 等. 活化相关分泌蛋白1单克隆抗体的制备及其在保守结构域鉴定中的应用[J]. 生物技术通讯, 2014, 25(2): 189-193. DOI: 10.3969/j.issn.1009-0002.2014.02.008 [9] Segura-Velazquez R, Perez-Torres A, Rosas G, et al.A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine[J]. Vaccine, 2006, 24(8): 1073-1080. DOI:10.1016/j.vaccine.2005.09.014 [10] Holland MJ, Harcus YM, Riches PL, et al.Proteins secreted by the parasitic nematode Nippostrongylus brasiliensis act as adjuvants for Th2 responses[J]. European J Immuno, 2000, 30(7): 1977-1987. DOI:10.1002/1521-4141(200007)30:7<1977::AID-IMMU1977>3.0.CO;2-3 [11] Visser A, Van Zeveren AM, Meyvis Y, et al.Gender-enriched transcription of activation associated secreted proteins in Ostertagia ostertagi[J]. International J Parasitol, 2008, 38(3/4): 455-65. DOI:10.1016/j.ijpara.2007.08.008 [12] Joseph GT, Huima T, Lustigman S.Characterization of an Onchocerca volvulus L3-specific larval antigen, Ov-ALT-1[J]. Molecular and biochemical parasitology, 1998, 96(1/2): 177-83. DOI:.org/10.1016/S0166-6851(98)00094-2 [13] MacDonald AJ, Turaga PS, Harmon-Brown C, et al. Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity[J]. Infection and immunity, 2002, 70(6): 2796-2804. DOI: 10.1128/IAI.70.6.2796-2804.2002 [14] Maizels RM, Balic A, Gomez-Escobar N, et al.Helminth parasites-masters of regulation[J]. Immunological reviews, 2004, 201:89-116. DOI:10.1111/j.0105-2896.2004.00191.x [15] Guo J, Yang Y, Xiao W, et al.A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein[J]. Vaccine, 2015, 33(16): 1974-80. DOI:10.1016/j.vaccine.2015.02.053